Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France

NCT02981901UNKNOWNOBSERVATIONAL

Summary

Key Facts

Lead Sponsor

Centre Leon Berard

Enrollment

376

Start Date

2017-01-01

Completion Date

2019-12-01

Study Type

OBSERVATIONAL

Official Title

Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France

Interventions

Patient with ovarian epithelial cancer

Conditions

Ovarian Epithelial Cancer

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* Ovarian epithelial cancer initially diagnosed in 2012
* Age \> 18 years old
* Residency in France (Rhône-Alpes region, District of Calvados and Cotes d'Or)
* First-line ovarian epithelial cancer

Exclusion Criteria:

* Relapsed ovarian epithelial cancer
* Non epithelial ovarian cancer

Outcome Measures

Primary Outcomes

Incremental cost-effectiveness ratio expressed in cost per relapse-free year gained

To perform a cost-effectiveness analysis in order to evaluate the most efficient organization for ovarian cancer in 1st line ot treatment

Time frame: 2 years after diagnosis

Secondary Outcomes

Incremental cost-effectiveness ratio expressed in cost per QALY(Quality-Adjusted Life Year) gained.

Time frame: 2 years after diagnosis

Budget impact analysis

Cost assessment performed retrospectively for each patient: hospital stays, visits and other health-related costs will be identified and measured based on the French national Health Insurance perspective. QALY (Quality-Adjusted Life Year)

Time frame: 2 years after diagnosis

Relapse-free survival (RFS)

Time frame: RFS will be assessed 2 years after diagnosis

Locations

Calvados registry, Caen, France

Côte d'or registry, Dijon, France

Oveval, Lyon, France